---
title: "Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021"
source_url: "https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421416"
source_layer: us_cdc_mmwr
category: surveillance_summary
date: 2021-04-29
confidence: 高
mmwr_volume: ""
mmwr_issue: ""
---

## 摘要

The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA's Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18-49 years.

## 詳細內容

The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA's Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18-49 years.

## 關鍵發現

(需要透過 WebFetch 補充或人工審核來提取關鍵發現)

---
*萃取時間: 2026-02-05T15:14:02Z*
*資料來源: CDC MMWR*
